{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:07:40Z","timestamp":1778836060146,"version":"3.51.4"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["454703\/2014-7"],"award-info":[{"award-number":["454703\/2014-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["479934\/2011-8"],"award-info":[{"award-number":["479934\/2011-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2010\\u221550883-8"],"award-info":[{"award-number":["2010\\u221550883-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2013\/08755-0"],"award-info":[{"award-number":["2013\/08755-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2015\/08693-0"],"award-info":[{"award-number":["2015\/08693-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2011-0947-1"],"award-info":[{"award-number":["2011-0947-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007404","name":"Clinical Trial Center, China Medical University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007404","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008353","name":"Funda\u00e7\u00e3o de Apoio ao Ensino, Pesquisa e Assist\u00eancia do Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005639","name":"Universidade de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.trsl.2018.11.001","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T01:03:18Z","timestamp":1542675798000},"page":"71-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers"],"prefix":"10.1016","volume":"206","author":[{"given":"Vin\u00edcius Pereira de","family":"Carvalho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Lopes","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila de Souza","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio Humberto Angotti","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitor Marcel","family":"Fa\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Jos\u00e9","family":"Candido dos Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Poersch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2018.11.001_bib0001","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/nrclinonc.2010.220","article-title":"Emerging molecular biomarkers\u2013blood-based strategies to detect and monitor cancer","volume":"8","author":"Hanash","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0002","series-title":"Tumor markers: physiology, pathobiology, technology, and clinical applications","first-page":"3","article-title":"Tumor markers: past, present, and future.","author":"Diamandis","year":"2002"},{"key":"10.1016\/j.trsl.2018.11.001_bib0003","series-title":"Abeloff: clinical Oncology","article-title":"Clinical chemistry: tumor markers","author":"Sokoll","year":"2004"},{"key":"10.1016\/j.trsl.2018.11.001_bib0004","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1074\/mcp.R300006-MCP200","article-title":"Tumor markers: from laboratory to clinical utility","volume":"2","author":"Schrohl","year":"2003","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.trsl.2018.11.001_bib0005","series-title":"Tumor biology and tumor markers","author":"Goedegebuure","year":"2004"},{"key":"10.1016\/j.trsl.2018.11.001_bib0006","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/ncponc0636","article-title":"Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy","volume":"3","author":"Andre","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0007","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.eururo.2007.09.036","article-title":"Challenges of cancer biomarker profiling","volume":"52","author":"Bensalah","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0008","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1464-410X.2007.06812.x","article-title":"The role of molecular markers in the staging of renal cell carcinoma","volume":"99","author":"Leppert","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.trsl.2018.11.001_bib0009","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1515\/CCLM.2001.197","article-title":"Determination of tumor markers in serum. Pitfalls and good practice","volume":"39","author":"Basuyau","year":"2001","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.trsl.2018.11.001_bib0010","first-page":"1","article-title":"Tumor markers in clinical practice: general principles and guidelines","volume":"30","author":"Sharma","year":"2009","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"10","key":"10.1016\/j.trsl.2018.11.001_bib0011","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1039\/C4CS00370E","article-title":"Cancer biomarker detection: recent achievements and challenges","volume":"44","author":"Wu","year":"2015","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.trsl.2018.11.001_bib0012","series-title":"Cecil textbook of medicine","article-title":"Tumor markers","author":"Cooper","year":"2004"},{"key":"10.1016\/j.trsl.2018.11.001_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4757-3587-1_3","article-title":"Early detection of ovarian cancer: promise and reality","volume":"107","author":"Bast","year":"2002","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0014","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1634\/theoncologist.11-6-541","article-title":"Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer","volume":"11","author":"Henry","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.trsl.2018.11.001_bib0015","first-page":"2791","volume":"19","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0016","series-title":"Cancer medicine","article-title":"Tumor markers and immunodiagnosis","author":"Bigbee","year":"2003"},{"key":"10.1016\/j.trsl.2018.11.001_bib0017","series-title":"Henry's clinical diagnosis and management by laboratory methods","first-page":"1353","article-title":"Diagnosis and management of cancer using serological tumor markers","author":"Lee","year":"2007"},{"key":"10.1016\/j.trsl.2018.11.001_bib0018","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jcla.1860050314","article-title":"Effect of different test designs of immunoassays on \"hook effect\" of CA 19-9 measurement","volume":"5","author":"Wu","year":"1991","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.trsl.2018.11.001_bib0019","series-title":"Sensible use of tumour markers","author":"Fateh-Moghadam","year":"1993"},{"key":"10.1016\/j.trsl.2018.11.001_bib0020","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/1097-0142(19911015)68:8<1758::AID-CNCR2820680819>3.0.CO;2-#","article-title":"Coordinate elevation of serum markers in ovarian cancer but not in benign disease","volume":"68","author":"Bast","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0021","first-page":"17","article-title":"Expression of monoclonal antibody-defined tumor markers in four carcinomas","volume":"19","author":"Wu","year":"1989","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.trsl.2018.11.001_bib0022","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0023","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/en.2011-2123","article-title":"Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy","volume":"153","author":"Romero","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.trsl.2018.11.001_bib0024","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.canep.2012.06.005","article-title":"The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer","volume":"36","author":"Gui","year":"2012","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0025","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2008.19.2484","article-title":"Development of a multimarker assay for early detection of ovarian cancer","volume":"28","author":"Yurkovetsky","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0026","article-title":"MET\/HGF signaling pathway in ovarian carcinoma: clinical implications and future direction","volume":"2012","author":"Mhawech-Fauceglia","year":"2012","journal-title":"Patholog Res Int"},{"key":"10.1016\/j.trsl.2018.11.001_bib0027","doi-asserted-by":"crossref","first-page":"R255","DOI":"10.1530\/ERC-12-0175","article-title":"Hormone response in ovarian cancer: time to reconsider as a clinical target?","volume":"19","author":"Modugno","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0028","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.2174\/138161212802002698","article-title":"Role of farletuzumab in epithelial ovarian carcinoma","volume":"18","author":"Jelovac","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.trsl.2018.11.001_bib0029","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cca.2012.10.058","article-title":"Detection and monitoring of ovarian cancer","volume":"415","author":"Su","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.trsl.2018.11.001_bib0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0031","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1586\/14789450.4.1.121","article-title":"Recent technical strategies to identify diagnostic biomarkers for ovarian cancer","volume":"4","author":"Ye","year":"2007","journal-title":"Expert Rev Proteomics"},{"issue":"Suppl 6","key":"10.1016\/j.trsl.2018.11.001_bib0032","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0033","doi-asserted-by":"crossref","first-page":"9536","DOI":"10.3390\/ijms14059536","article-title":"Targeting signaling pathways in epithelial ovarian cancer","volume":"14","author":"Smolle","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2018.11.001_bib0034","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-013-9456-2","article-title":"Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition","volume":"33","author":"Thibault","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.trsl.2018.11.001_bib0035","first-page":"1","article-title":"Proteomic analysis of ovarian cancer tumor fluid is a rich source of potential biomarkers","volume":"S5","author":"Poersch","year":"2014","journal-title":"J Proteomics Bioinf"},{"issue":"1","key":"10.1016\/j.trsl.2018.11.001_bib0036","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10555-014-9547-8","article-title":"Proteomics of ovarian cancer: functional insights and clinical applications","volume":"34","author":"Elzek","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.trsl.2018.11.001_bib0037","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0038","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/humrep\/der211","article-title":"The 'incessant menstruation' hypothesis: a mechanistic ovarian cancer model with implications for prevention","volume":"26","author":"Vercellini","year":"2011","journal-title":"Hum Reprod"},{"key":"10.1016\/j.trsl.2018.11.001_bib0039","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12672-010-0054-2","article-title":"Microenvironment and pathogenesis of epithelial ovarian cancer","volume":"1","author":"Saad","year":"2010","journal-title":"Horm Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ygyno.2011.10.001","article-title":"The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations","volume":"124","author":"Munksgaard","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0041","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2013shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0042","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2018.11.001_bib0043","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0044","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0045","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0046","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/740968","article-title":"Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma","volume":"2010","author":"Gilks","year":"2010","journal-title":"J Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0047","doi-asserted-by":"crossref","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","article-title":"Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis","volume":"309","author":"Yeung","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0048","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cll.2009.01.007","article-title":"Development of high-throughput mass spectrometry-based approaches for cancer biomarker discovery and implementation","volume":"29","author":"Hood","year":"2009","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.trsl.2018.11.001_bib0049","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.7314\/APJCP.2014.15.20.8529","article-title":"Research progress in applying proteomics technology to explore early diagnosis biomarkers of breast cancer, lung cancer and ovarian cancer","volume":"15","author":"Luo","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.trsl.2018.11.001_bib0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jprot.2013.04.007","article-title":"Innovations in proteomic profiling of cancers: alternative splice variants as a new class of cancer biomarker candidates and bridging of proteomics with structural biology","volume":"90","author":"Omenn","year":"2013","journal-title":"J Proteomics"},{"key":"10.1016\/j.trsl.2018.11.001_bib0051","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.3390\/ijms13089545","article-title":"Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death","volume":"13","author":"Castells","year":"2012","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2018.11.001_bib0052","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2018.11.001_bib0053","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trsl.2018.11.001_bib0054","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2018.11.001_bib0055","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.devcel.2010.05.012","article-title":"Tumors as organs: complex tissues that interface with the entire organism","volume":"18","author":"Egeblad","year":"2010","journal-title":"Dev cell"},{"key":"10.1016\/j.trsl.2018.11.001_bib0056","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bulcan.2014.12.006","article-title":"Intratumoral heterogeneity and consequences for targeted therapies","volume":"102","author":"Turtoi","year":"2015","journal-title":"Bull Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0057","first-page":"105","article-title":"Tumor heterogeneity: causes and consequences","volume":"1805","author":"Marusyk","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2018.11.001_bib0058","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/508052a","article-title":"Cancer: clonal cooperation","volume":"508","author":"Polyak","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2018.11.001_bib0059","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trsl.2018.11.001_bib0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrc3298","article-title":"Evolutionary dynamics of carcinogenesis and why targeted therapy does not work","volume":"12","author":"Gillies","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0061","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fonc.2015.00149","article-title":"Harnessing pandemonium: the clinical implications of tumor heterogeneity in ovarian cancer","volume":"5","author":"Blagden","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0062","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ygyno.2009.09.005","article-title":"Application of proteomics in ovarian cancer: which sample should be used?","volume":"115","author":"Cadron","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0063","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/pr1008515","article-title":"On the development of plasma protein biomarkers","volume":"10","author":"Surinova","year":"2011","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0064","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/pmic.201100654","article-title":"The ovarian cancer-derived secretory\/releasing proteome: a repertoire of tumor markers","volume":"12","author":"Zhang","year":"2012","journal-title":"Proteomics"},{"key":"10.1016\/j.trsl.2018.11.001_bib0065","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1002\/jcb.24250","article-title":"Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach","volume":"113","author":"Wang","year":"2012","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.trsl.2018.11.001_bib0066","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/179040","article-title":"Proteomics analysis for finding serum markers of ovarian cancer","volume":"2014","author":"Cheng","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.trsl.2018.11.001_bib0067","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/ijc.30020","article-title":"Protein Z: a putative novel biomarker for early detection of ovarian cancer","volume":"138","author":"Russell","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0068","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/prca.201400063","article-title":"Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies","volume":"8","author":"Timms","year":"2014","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.trsl.2018.11.001_bib0069","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1559-0275-9-14","article-title":"Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers","volume":"9","author":"Kristjansdottir","year":"2012","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.trsl.2018.11.001_bib0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1559-0275-10-4","article-title":"Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ","volume":"10","author":"Kristjansdottir","year":"2013","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.trsl.2018.11.001_bib0071","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jprot.2016.05.005","article-title":"A proteomic signature of ovarian cancer tumor fluid identified by high throughput and verified by targeted proteomics","volume":"145","author":"Poersch","year":"2016","journal-title":"J Proteomics"},{"key":"10.1016\/j.trsl.2018.11.001_bib0072","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/cam4.282","article-title":"Early inflammatory response in epithelial ovarian tumor cyst fluids","volume":"3","author":"Kristjansdottir","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.trsl.2018.11.001_bib0073","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1021\/pr1011087","article-title":"In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry","volume":"10","author":"Elschenbroich","year":"2011","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0074","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1074\/mcp.M114.041194","article-title":"Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication","volume":"13","author":"Shender","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.trsl.2018.11.001_bib0075","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1021\/pr0703223","article-title":"A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatics analyses to identify putative biomarkers","volume":"7","author":"Gortzak-Uzan","year":"2008","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0076","doi-asserted-by":"crossref","first-page":"e25056","DOI":"10.1371\/journal.pone.0025056","article-title":"Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation","volume":"6","author":"Hoskins","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2018.11.001_bib0077","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1074\/mcp.M110.000802","article-title":"Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation","volume":"9","author":"Wang","year":"2010","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.trsl.2018.11.001_bib0078","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/prca.201200086","article-title":"Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue","volume":"7","author":"Thompson","year":"2013","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.trsl.2018.11.001_bib0079","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/prca.201200046","article-title":"Proteomic workflow for analysis of archival formalin-fixed and paraffin-embedded clinical samples to a depth of 10 000 proteins","volume":"7","author":"Wisniewski","year":"2013","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.trsl.2018.11.001_bib0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/prca.201400106","article-title":"Using tissue samples for proteomic studies-critical considerations","volume":"9","author":"Becker","year":"2015","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.trsl.2018.11.001_bib0081","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/33.8.3894502","article-title":"Formaldehyde fixation","volume":"33","author":"Fox","year":"1985","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.trsl.2018.11.001_bib0082","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/mp.54.4.253","article-title":"Application of laser capture microdissection and proteomics in colon cancer","volume":"54","author":"Lawrie","year":"2001","journal-title":"Mol Pathol: MP"},{"key":"10.1016\/j.trsl.2018.11.001_bib0083","doi-asserted-by":"crossref","first-page":"83187","DOI":"10.18632\/oncotarget.13077","article-title":"Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics","volume":"7","author":"Qu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.11.001_bib0084","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-10-299","article-title":"Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases","volume":"10","author":"Wang","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0085","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/204946","article-title":"Tumor lymphangiogenesis as a potential therapeutic target","volume":"2012","author":"Duong","year":"2012","journal-title":"J Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0086","first-page":"405","article-title":"Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis","volume":"32","author":"Baronzio","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0087","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.matbio.2010.08.001","article-title":"Interaction between the extracellular matrix and lymphatics: consequences for lymphangiogenesis and lymphatic function","volume":"29","author":"Wiig","year":"2010","journal-title":"Matrix Biol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0088","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1152\/physrev.00037.2011","article-title":"Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer","volume":"92","author":"Wiig","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.trsl.2018.11.001_bib0089","doi-asserted-by":"crossref","first-page":"e19217","DOI":"10.1371\/journal.pone.0019217","article-title":"A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissue","volume":"6","author":"Haslene-Hox","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2018.11.001_bib0090","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/0008-5472.CAN-08-3087","article-title":"In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding","volume":"69","author":"Faca","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0091","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cbpa.2008.02.010","article-title":"Proteomics-driven cancer biomarker discovery: looking to the future","volume":"12","author":"Simpson","year":"2008","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0092","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1021\/pr100904q","article-title":"Advances in proximal fluid proteomics for disease biomarker discovery","volume":"9","author":"Teng","year":"2010","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0093","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1016\/j.bbapap.2013.01.028","article-title":"Interstitial fluid-a reflection of the tumor cell microenvironment and secretome","volume":"1834","author":"Haslene-Hox","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2018.11.001_bib0094","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.11.001_bib0095","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/475983","article-title":"Potential markers for detection and monitoring of ovarian cancer","volume":"2011","author":"Rein","year":"2011","journal-title":"J Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0096","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1006\/gyno.1998.5198","article-title":"The chemotactic cytokine interleukin-8\u2013a cyst fluid marker for malignant epithelial ovarian cancer?","volume":"71","author":"Ivarsson","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0097","first-page":"65","article-title":"Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts","volume":"21","author":"Sundfeldt","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0098","first-page":"3294","article-title":"Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer","volume":"58","author":"Wahlberg","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0099","first-page":"7507","article-title":"Calgranulins in cystic fluid and serum from patients with ovarian carcinomas","volume":"63","author":"Ott","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0100","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0002-9378(74)90021-0","article-title":"Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer","volume":"119","author":"Feldman","year":"1974","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0101","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","article-title":"Malignant ascites: past, present, and future","volume":"198","author":"Adam","year":"2004","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.trsl.2018.11.001_bib0102","first-page":"1663","article-title":"The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma","volume":"32","author":"Feldman","year":"1972","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0103","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","article-title":"Mechanisms of transcoelomic metastasis in ovarian cancer","volume":"7","author":"Tan","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0104","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1023791229361","article-title":"Intraperitoneal cancer dissemination: mechanisms of the patterns of spread","volume":"22","author":"Carmignani","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.trsl.2018.11.001_bib0105","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/sj.bjc.6602495","article-title":"Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma","volume":"92","author":"Ahmed","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0106","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.1441","article-title":"Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid","volume":"201","author":"Ahmed","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0107","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ijc.22840","article-title":"Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K\/Akt pathway in human ovarian carcinoma cells","volume":"121","author":"Lane","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0108","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1101\/gad.1636908","article-title":"Migratory neighbors and distant invaders: tumor-associated niche cells","volume":"22","author":"Wels","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.trsl.2018.11.001_bib0109","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature03096","article-title":"Stromal fibroblasts in cancer initiation and progression","volume":"432","author":"Bhowmick","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2018.11.001_bib0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.critrevonc.2015.04.002","article-title":"Exosomes: potent regulators of tumor malignancy and potential bio-tools in clinical application","volume":"95","author":"Guo","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0111","doi-asserted-by":"crossref","first-page":"e46858","DOI":"10.1371\/journal.pone.0046858","article-title":"Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors","volume":"7","author":"Latifi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2018.11.001_bib0112","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0113","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1002\/pmic.200401246","article-title":"Characterization of the human blood plasma proteome","volume":"5","author":"Shen","year":"2005","journal-title":"Proteomics"},{"key":"10.1016\/j.trsl.2018.11.001_bib0114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1476-4598-5-55","article-title":"Pathway-specific differences between tumor cell lines and normal and tumor tissue cells","volume":"5","author":"Ertel","year":"2006","journal-title":"Mol Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0115","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1158\/0008-5472.CAN-03-3383","article-title":"A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins","volume":"64","author":"Stein","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0116","doi-asserted-by":"crossref","first-page":"18708","DOI":"10.1073\/pnas.1111840108","article-title":"Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance","volume":"108","author":"Gillet","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2018.11.001_bib0117","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1073\/pnas.0408105102","article-title":"Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI)","volume":"102","author":"Sandberg","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2018.11.001_bib0118","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2018.11.001_bib0119","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/msb.2011.82","article-title":"The quantitative proteome of a human cell line","volume":"7","author":"Beck","year":"2011","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1752-0509-5-17","article-title":"Initial characterization of the human central proteome","volume":"5","author":"Burkard","year":"2011","journal-title":"BMC Syst Biol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0121","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.molcel.2013.01.029","article-title":"The coming age of complete, accurate, and ubiquitous proteomes","volume":"49","author":"Mann","year":"2013","journal-title":"Mol Cell"},{"key":"10.1016\/j.trsl.2018.11.001_bib0122","doi-asserted-by":"crossref","first-page":"12645","DOI":"10.1038\/ncomms12645","article-title":"Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status","volume":"7","author":"Coscia","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2018.11.001_bib0123","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/gm282","article-title":"Why have protein biomarkers not reached the clinic?","volume":"3","author":"Hanash","year":"2011","journal-title":"Genome Med"},{"key":"10.1016\/j.trsl.2018.11.001_bib0124","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.critrevonc.2015.07.006","article-title":"Proteomics in cancer research: are we ready for clinical practice?","volume":"96","author":"Maes","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0125","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2018.11.001_bib0126","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000050638","article-title":"The CA 125 gene: an extracellular superstructure dominated by repeat sequences","volume":"22","author":"O'Brien","year":"2001","journal-title":"Tumour Biol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0127","doi-asserted-by":"crossref","first-page":"27371","DOI":"10.1074\/jbc.M103554200","article-title":"Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16","volume":"276","author":"Yin","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2018.11.001_bib0128","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2018.11.001_bib0129","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","article-title":"Structure and function of the cell surface (tethered) mucins","volume":"70","author":"Hattrup","year":"2008","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0130","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/bjc.2011.34","article-title":"Downregulation of cell surface CA125\/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH: OVCAR3 ovarian carcinoma cells","volume":"104","author":"Comamala","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0131","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ygyno.2011.04.032","article-title":"More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis","volume":"121","author":"Bast","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0132","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Mol Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0133","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ajog.2008.04.009","article-title":"The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125","volume":"199","author":"Nossov","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0134","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2217\/bmm.12.70","article-title":"From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade","volume":"6","author":"Leung","year":"2012","journal-title":"Biomarkers Med"},{"key":"10.1016\/j.trsl.2018.11.001_bib0135","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4331\/wjbc.v5.i3.286","article-title":"2014, can we do better than CA125 in the early detection of ovarian cancer?","volume":"5","author":"Cohen","year":"2014","journal-title":"World J Biol Chem"},{"key":"10.1016\/j.trsl.2018.11.001_bib0136","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.1200\/JCO.2005.01.6642","article-title":"Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer","volume":"23","author":"Menon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0137","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0138","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","article-title":"Does HE4 have a role as biomarker in the recurrence of ovarian cancer?","volume":"33","author":"Plotti","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0139","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1165\/rcmb.2004-0250OC","article-title":"The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses","volume":"32","author":"McMichael","year":"2005","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0378-1119(99)00342-X","article-title":"Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas","volume":"238","author":"Schummer","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.trsl.2018.11.001_bib0141","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-1119(99)00035-9","article-title":"Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray","volume":"229","author":"Wang","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.trsl.2018.11.001_bib0142","first-page":"6281","article-title":"Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer","volume":"60","author":"Hough","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.11.001_bib0143","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ygyno.2004.11.039","article-title":"Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling","volume":"96","author":"Gilks","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0144","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ygyno.2009.09.041","article-title":"Current state of biomarker development for clinical application in epithelial ovarian cancer","volume":"116","author":"Moore","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0145","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","article-title":"Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts","volume":"100","author":"Huhtinen","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.12.029","article-title":"Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders","volume":"206","author":"Moore","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0147","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1177\/0192623312444765","article-title":"Tissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats","volume":"40","author":"Vinken","year":"2012","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0148","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1158\/1055-9965.EPI-10-0580","article-title":"The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers","volume":"19","author":"Zhang","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.trsl.2018.11.001_bib0149","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass","volume":"118","author":"Moore","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0150","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0151","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/CCLM.2011.085","article-title":"Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population","volume":"49","author":"Kim","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.trsl.2018.11.001_bib0152","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cca.2011.04.028","article-title":"HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm","volume":"412","author":"Ruggeri","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.trsl.2018.11.001_bib0153","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-11-0635","article-title":"Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management","volume":"20","author":"Bandiera","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.trsl.2018.11.001_bib0154","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0156","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2012.07.106","article-title":"Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass","volume":"127","author":"Karlsen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0157","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2013.01.018","article-title":"A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass","volume":"129","author":"Kaijser","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0158","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1600-0412.2012.01359.x","article-title":"Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass","volume":"91","author":"Hakansson","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"10.1016\/j.trsl.2018.11.001_bib0159","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ygyno.2015.06.021","article-title":"A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - an international multicenter study in women with an ovarian mass","volume":"138","author":"Karlsen","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40291-013-0027-6","article-title":"Biomarker testing for ovarian cancer: clinical utility of multiplex assays","volume":"17","author":"Nolen","year":"2013","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.trsl.2018.11.001_bib0161","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm","volume":"104","author":"Van Gorp","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0162","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?","volume":"49","author":"Montagnana","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.trsl.2018.11.001_bib0163","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2012.11.026","article-title":"Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome","volume":"128","author":"Sandri","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0164","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3802\/jgo.2011.22.4.244","article-title":"Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass","volume":"22","author":"Partheen","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0165","doi-asserted-by":"crossref","first-page":"437","DOI":"10.6061\/clinics\/2012(05)06","article-title":"A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses","volume":"67","author":"Anton","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.trsl.2018.11.001_bib0166","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2012.09.034","article-title":"The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass","volume":"128","author":"Chan","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0167","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3802\/jgo.2015.26.1.46","article-title":"Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings","volume":"26","author":"Wilailak","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0168","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/humupd\/dmt059","article-title":"Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis","volume":"20","author":"Kaijser","year":"2014","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.trsl.2018.11.001_bib0169","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejogrb.2012.10.036","article-title":"Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis","volume":"167","author":"Lin","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejogrb.2008.08.011","article-title":"Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review","volume":"142","author":"Medeiros","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.trsl.2018.11.001_bib0171","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1590\/S1516-31802002000300003","article-title":"Risk-of-malignancy index in preoperative evaluation of clinically restricted ovarian cancer","volume":"120","author":"Torres","year":"2002","journal-title":"Sao Paulo Med J"},{"key":"10.1016\/j.trsl.2018.11.001_bib0172","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12885-015-1319-5","article-title":"Investigating the performance and cost-effectiveness of the simple ultrasound-based rules compared to the risk of malignancy index in the diagnosis of ovarian cancer (SUBSONiC-study): protocol of a prospective multicenter cohort study in the Netherlands","volume":"15","author":"Meys","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trsl.2018.11.001_bib0173","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2014.02.010","article-title":"The effect of ovarian imaging on the clinical interpretation of a multivariate index assay","volume":"211","author":"Goodrich","year":"2014","journal-title":"Am J Obstet Gynecol"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418302147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418302147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:13:06Z","timestamp":1778832786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524418302147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":173,"alternative-id":["S1931524418302147"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2018.11.001","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2018.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}